Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 355

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 355
---
-capital. As of September 30, 2025, the Company had (i) 2,848,096 Purchase Warrants issued and outstanding at an exercise price of $5.50 per share to purchase shares of the Company's common stock, and (ii) 1,077,764 Pre-Funded Warrants issued and outstanding at an exercise price of $0.001 per share to purchase shares of the Company's common stock. On October 6, 2025, certain purchasers from the August 2025 Private Placement exercised an aggregate of 1,077,764 Pre-Funded Warrants previously issued to them pursuant to the August 2025 Purchase Agreement. Each such exercise was made pursuant to the cashless exercise provision of the applicable Pre-Funded Warrant, such that an aggregate of 166 shares of common stock were withheld in lieu of a cash payment of the $0.001 exercise price for each Pre-Funded Warrant, and the exercising purchasers were issued an aggregate of 1,077,598 shares of common stock. See "Note 12 - Subsequent Events" for additional information related to the cashless exercise of the Pre-Funded Warrants.September 2025 Aventis (Sanofi) Private PlacementOn September 24, 2025, the Company entered into the September 2025 Purchase Agreement with Aventis, pursuant to which the Company agreed to sell securities to Aventis in the September 2025 Private Placement. The September 2025 Purchase Agreement provided for the sale and issuance by the Company to Aventis of an aggregate of 2,708,559 shares of its common stock at a purchase price of $9.23 per share. The Company received aggregate net proceeds of $23.3 million from the September 2025 Private Placement, after deducting placement agent discounts and commissions, but before deducting placement costs payable by the Company, which were estimated to be approximately $0.2 million. The September 2025 Private Placement closed on September 26, 2025.Pursuant to the September 2025 Purchase Agreement, the Company also agreed to (i) notify Aventis within three business days of the Company engaging in discussions with any third party regarding, or the Company’s board of directors authorizing the Company to pursue or initiate a process to pursue, any transaction that would be reasonably expected to result in a change of control of the Company or an affiliate of the Company (a “Change of Control”) or any other license